At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 163 enrolled
Drug / intervention
Durvalumabdrug
Likely dose
Durvalumab 1500mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Multi-Center, Global Study to Evaluate Long Term Safety and Efficacy in Patients Who Are Receiving or Who Previously Received Durvalumab in Other Protocols (WAVE)
In Brief
A Phase 4 clinical trial evaluating Durvalumab for Solid Tumor. Completed, enrolled 163 participants across 116 sites in 31 countries.
Detailed Summary
The aims of the study are to monitor the long-term safety of durvalumab, to provide continued treatment or retreatment with durvalumab to eligible patients, and to collect overall survival (OS) information.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSolid Tumor
CountriesArgentina, Australia, Belgium, Brazil, Bulgaria, Canada, Chile, Czechia, France, Germany, Greece, Hungary, India, Israel, Japan, Malaysia, Netherlands, Poland, Romania, Russia, Serbia, South Korea, Spain, Switzerland, Taiwan, Thailand, Turkey (Türkiye), Ukraine, United Kingdom, United States, Vietnam
CollaboratorsIQVIA Pty Ltd, Parexel, Medidata Solutions, CISCRP
Timeline
Phase 4CompletedFinished
2020202120222023202420252026
First PostedSep 2019
Enrollment StartSep 2019
Primary CompletionOct 2022
Study CompletionOct 2024
TodayJul 2026
First PostedSep 4, 2019
Enrollment StartSep 5, 2019
Primary CompletionOct 31, 2022
Study CompletionOct 31, 2024
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 6.8 years ago
Interventions
Durvalumabdrug
IV infusion q4w with 1500mg durvalumab until progressive disease